Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 19, 2023, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Acalabrutinib Capsules, 100 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 19, 2023, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Acalabrutinib Capsules, 100 mg".